Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy

Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy

This article dials with the new opportunities for the treatment of HER2-positive breast cancer with the involvement of the central nervous system (CNS). In CEREBEL study was shown that trastuzumab was not inferior to lapatinib concerning the reduction the incidence of brain metastases and had statis...

Full description

Bibliographic Details
Main Authors:	E V Artamonova, L V Manziuk
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2015-06-01
Series:	Современная онкология
Subjects:	t-dm1 her2-positive breast cancer brain metastases trastuzumab lapatinib pertuzumab
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/27003

Similar Items

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Personalized approach to HER2-positive advanced breast cancertherapy
by: M B Stenina
Published: (2014-09-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
by: Maria Moritti, et al.
Published: (2018-06-01)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
by: Inge M. Werter, et al.
Published: (2022-11-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Systemic control of cerebral metastases in a patient with HER2-positive metastatic breast cancer. Clinical case
by: S. F. Menshikova, et al.
Published: (2019-06-01)

Long-term survival in a young woman with recurrent HER2-positive breast cancer.
by: Gianluca Cotroneo
Published: (2018-06-01)

All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
by: Hanan Shawky, et al.
Published: (2014-12-01)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
by: Thibaut Sanglier, et al.
Published: (2023-06-01)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
by: Luai S. Al Rabadi, et al.
Published: (2021-10-01)

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
by: Michela Donadio
Published: (2018-06-01)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine
by: Audrey Mailliez, et al.
Published: (2014-08-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
by: Michael P. Lux, et al.
Published: (2018-12-01)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
by: Xiaoyun Liu, et al.
Published: (2022-09-01)

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01)

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
by: Giuseppina Rosaria Rita Ricciardi, et al.
Published: (2018-01-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
by: Ana Carla Castro-Guijarro, et al.
Published: (2023-09-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
by: Eurydice Angeli, et al.
Published: (2024-04-01)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
by: Fangfang Duan, et al.
Published: (2022-03-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
by: Azzurra Irelli, et al.
Published: (2022-06-01)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
by: Shengnan Yu, et al.
Published: (2017-11-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Calcium Electroporation for Management of Cutaneous Metastases in HER2-Positive Breast Cancer: A Case Report
by: Katrine Borres Jensen, et al.
Published: (2022-11-01)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
by: Sanne L. de Haas, et al.
Published: (2023-01-01)

Breast cancer: from guidelines to personalized oncology
by: Conte PierFranco, et al.
Published: (2013-06-01)